Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Invested Capital (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Invested Capital for 10 consecutive years, with $26.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital fell 59.56% year-over-year to $26.5 million, compared with a TTM value of $26.5 million through Sep 2025, down 59.56%, and an annual FY2024 reading of $46.1 million, down 56.85% over the prior year.
  • Invested Capital was $26.5 million for Q3 2025 at Spero Therapeutics, down from $32.8 million in the prior quarter.
  • Across five years, Invested Capital topped out at $118.8 million in Q1 2021 and bottomed at $26.5 million in Q3 2025.
  • Average Invested Capital over 5 years is $67.3 million, with a median of $64.8 million recorded in 2023.
  • The sharpest move saw Invested Capital tumbled 70.84% in 2022, then skyrocketed 64.61% in 2023.
  • Year by year, Invested Capital stood at $88.3 million in 2021, then decreased by 13.99% to $75.9 million in 2022, then surged by 40.77% to $106.9 million in 2023, then plummeted by 56.85% to $46.1 million in 2024, then plummeted by 42.56% to $26.5 million in 2025.
  • Business Quant data shows Invested Capital for SPRO at $26.5 million in Q3 2025, $32.8 million in Q2 2025, and $33.8 million in Q1 2025.